Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Triple (ParticipantInvestigatorOutcomes Assessor)
Primary outcome measures:
American College of Rheumatology (ACR) 50 response at Week 16
published the results of bimekizumab 160 mg every 4 weeks or adalimumab 40 mg every 2 weeks to patients with a documented diagnosis of adult-onset psoriatic arthritis that met the Classification Criteria for Psoriatic Arthritis for at least 6 months before screening from a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled trial with 852 subjects.
The authors' conclusion was: Bimekizumab treatment had superior improvements in joint, skin, and radiographic efficacy o…